One of three males in the TransCon PTH 24 μg PTH(1‐34)/day MAD cohort experienced symptomatic hypercalcemia (11.68 mg/dL) and discontinued dosing after the sixth dose; a second male subject was asymptomatic despite an albumin‐adjusted sCa of 11.76 mg/dL on day 11; none of the male subjects experienced vasodilatory AEs. The gene discussed is PTH; the disease is hypercalcemia disease.